-
Mashup Score: 163
DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. A statistically significant improvement in progression-free survival (PFS) versus T-DM1 was reported in the primary analysis. Here, we report exploratory efficacy data in patients with and without brain metastases (BMs) at baseline.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here? - 3 day(s) ago
In this issue of ESMO Open, Hurvitz and colleagues1 report an exploratory analysis of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in the subgroup of 82 patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and baseline brain metastases (BrMs) from the landmark DESTINY-Breast03 clinical trial. Impressively, the intracranial response rate (i-ORR) was 65.7% with T-DXd versus 34.3% with T-DM1 confirming antibody–drug conjugates (ADCs) as a promising strategy in treating breast cancer BrMs.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (@drsarahsam) and Nancy Lin (@nlinmd) from @DFCI_BreastOnc. https://t.co/QkQ1XNVmZU https://t.co/k3TanjNSiH https://t.co/TuycSzyo5Q
-
-
Mashup Score: 71
DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. A statistically significant improvement in progression-free survival (PFS) versus T-DM1 was reported in the primary analysis. Here, we report exploratory efficacy data in patients with and without brain metastases (BMs) at baseline.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Out in @ESMO_Open the intracranial activity of T-DXd vs T-DM1 in the DESTINY-Breast03 phase 3 trial. Among patients with active brain mets, IC-ORR was 65.7% with T-DXd vs 34.3% with T-DM1. Accompanied by a podcast 🎙️ & an editorial by @drsarahsam @nlinmd. https://t.co/O8gytcXcq3 https://t.co/qTkTxbhGua
-
-
Mashup Score: 28
Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody–drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have shown to be highly effective in the treatment of MBC. However, there are only limited data whether these macromolecules are also effective in patients with BCBMs. We therefore aimed to examine the efficacy of SG and T-DXd in patients with stable and active BCBMs in a multicenter real-world analysis.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the real-world intracranial activity of T-DXd & SG for breast cancer brain mets (BCBM)? In this 🇩🇪 cohort of 26 patients with BCBM, icDCR was 42% in patients receiving SG for triple negative BCBM and 88% if receiving T-DXd for HER2+/HER2-low BCBM. https://t.co/GPZa0sRCzA https://t.co/aak6AY9N0L
-
-
Mashup Score: 26
The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk for a recurrence is high for many patients, including those with lymph node-negative melanoma, thus necessitating additional therapies beyond surgery. With the advent of anti-programmed cell death protein 1 (PD-1)-based immunotherapies, which are vastly more effective compared to previous standard-of-care treatments in the advanced setting, the landscape of adjuvant therapy has fundamentally changed in recent years.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
Adjuvant immunotherapy for melanoma patients: progress and opportunities. Don’t miss the latest Open Access review by Drs. Sussman and Ott, recapitulating recent advancements and future perspectives in the curative treatment of melanoma with immunotherapy. https://t.co/DxXIOX9hZ1 https://t.co/Y7oZhAVKOf
-
-
Mashup Score: 36Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin - 14 day(s) ago
Triple-negative breast cancer (TNBC) subtyping by gene profiling has provided valuable clinical information. Here, we aimed to evaluate the relevance of TNBC subtyping using immunohistochemistry (IHC), which could be a more clinically practical approach, for prognostication and applications in patient management.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
TNBC is commonly treated as a unitary entity, although distinct subtypes have been recognized within this definition. Here, Dr. Hu et al. used IHC-based subtyping among 123 patients with TNBC, demonstrating distinct features and outcomes across subtypes. https://t.co/lIeGdCVpdX https://t.co/h4dkIh9qZP
-
-
Mashup Score: 42
Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
What are the treatment patterns and outcomes for patients with BRAF-mutant mCRC after progression to encorafenib/cetiximab? In this article, Dr. Germani et al. report data from a large 🇮🇹 cohort, suggesting improved outcomes when TT is administered early. https://t.co/hsEW5hfRn2 https://t.co/OTxrV66e69
-
-
Mashup Score: 3
The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer. In this study, we present the outcomes of the HER2DX risk-score within the most recent release of the Sweden Cancerome Analysis Network—Breast (SCAN-B) HER2+ cohort. This updated examination benefits from a larger patient sample, an extended follow-up duration, and detailed treatment information.
Source: www.esmoopen.comCategories: General Medicine News, Onc News and JournalsTweet-
📰 Hot off the press: among 757 patients with early HER2+ breast cancer in the Swedish SCAN-B cohort, the HER2DX risk-score as a continuous variable was found significantly associated with OS after adjustment for clinical variables and treatment regimen. https://t.co/tubg5vWo7L https://t.co/sGpnCxMDof
-
-
Mashup Score: 81Management of infusion-related reactions in cancer therapy: strategies and challenges - 2 month(s) ago
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 80Management of infusion-related reactions in cancer therapy: strategies and challenges - 2 month(s) ago
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
Excited to share our publication of T-DXd vs. T-DM1 in pts with brain 🧠 mets from DB-03. ⭐️ PFS 15 months w/T-DXd vs. 3 months w/ T-DM1 Trastuzumab deruxtecan vs trastuzumab emtansine in brain metastases in DESTINY-Breast03 trial - ESMO Open https://t.co/PyTALNo8nu